Abstract:INTRODUCTION:X-ray crystallography plays an important role in structure-based drug design (SBDD), and accurate analysis of crystal structures of target macromolecules and macromolecule-ligand complexes is critical at all stages. However, whereas there has been significant progress in improving methods of structural biology, particularly in X-ray crystallography, corresponding progress in the development of computational methods (such as in silico high-throughput screening) is still on the horizon. Crystal structures can be overinterpreted and thus bias hypotheses and follow-up experiments. As in any experimental science, the models of macromolecular structures derived from X-ray diffraction data have their limitations, which need to be critically evaluated and well understood for structure-based drug discovery.AREAS COVERED:This review describes how the validity, accuracy and precision of a protein or nucleic acid structure determined by X-ray crystallography can be evaluated from three different perspectives: i) the nature of the diffraction experiment; ii) the interpretation of an electron density map; and iii) the interpretation of the structural model in terms of function and mechanism. The strategies to optimally exploit a macromolecular structure are also discussed in the context of 'Big Data' analysis, biochemical experimental design and structure-based drug discovery.EXPERT OPINION:Although X-ray crystallography is one of the most detailed 'microscopes' available today for examining macromolecular structures, the authors would like to re-emphasize that such structures are only simplified models of the target macromolecules. The authors also wish to reinforce the idea that a structure should not be thought of as a set of precise coordinates but rather as a framework for generating hypotheses to be explored. Numerous biochemical and biophysical experiments, including new diffraction experiments, can and should be performed to verify or falsify these hypotheses. X-ray crystallography will find its future application in drug discovery by the development of specific tools that would allow realistic interpretation of the outcome coordinates and/or support testing of these hypotheses.

Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Computational Methods for Structure-Based Drug Design Through System Biology.

Structure-Based Drug Design Strategies and Challenges

Structure-based drug design: aiming for a perfect fit

Recent Trends in Drug Design and Discovery

Systematic computational strategies for identifying protein targets and lead discovery

Computational approaches streamlining drug discovery

Structure-based drug design: From nucleic acid to membrane protein targets

Identifying targets for drug discovery using bioinformatics

X-ray Crystallography over the Past Decade for Novel Drug Discovery - Where Are We Heading Next?

The Synergy of Molecular Docking and Bioinformatics: An in Depth Review in Drug Discovery

Bioinformatics Techniques For Drug Discovery: Applications For Complex Diseases

The Future of Crystallography in Drug Discovery.

Recent progress on structural bioinformatics research of cytochrome P450 and its impact on drug discovery.

Structure-Based Approach For In-Silico Drug Designing

Molecular docking as a popular tool in drug design, an in silico travel

Bioinformatics Algorithms for Molecular Docking: IT and Chemistry Synergy

Structure-Based Virtual Screening of Chemical Libraries for Drug Discovery

Towards Structure-Based Protein Drug Design